Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD19 Positive Lymphoma | Phase 1 | China | 01 Apr 2017 | |
Refractory Lymphoma | Clinical | China | 10 Apr 2018 | |
Acute Lymphoblastic Leukemia | Clinical | China | 01 Nov 2015 | |
Diffuse Large B-Cell Lymphoma | Clinical | China | 02 Jul 2015 |
Phase 2 | 51 | qsrbxbyeoe(truayyuxpp) = jumdasnsku uwqsxfxomz (anbtnksfzt ) View more | Positive | 23 Nov 2020 |